Ligand Pharmaceuticals Inc. (LGND)

120.86
0.02 0.02
NASDAQ : Health Technology
Prev Close 120.88
Open 121.53
Day Low/High 120.12 / 122.84
52 Wk Low/High 98.56 / 278.62
Volume 463.36K
Avg Volume 646.70K
Exchange NASDAQ
Shares Outstanding 22.00M
Market Cap 2.66B
EPS 6.80
P/E Ratio 16.91
Div & Yield N.A. (N.A)

Latest News

Ligand Announces Investment In Dianomi Therapeutics

Ligand Announces Investment In Dianomi Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces closing an investment in Dianomi Therapeutics, Inc.

Ligand Partner Seelos Therapeutics Becomes A Public Company

Ligand Partner Seelos Therapeutics Becomes A Public Company

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) partner Seelos Therapeutics, Inc.

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

Nvidia, Microsoft, Kimberly-Clark: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Nvidia, Microsoft, Kimberly-Clark, Ligand Pharmaceutical, Edison International, Consolidated Edison, ArcBest and more.

Snapping the Win Streak: Cramer's 'Mad Money' Recap (Tuesday 1/22/19)

Snapping the Win Streak: Cramer's 'Mad Money' Recap (Tuesday 1/22/19)

From earnings to oil and fund managers, Jim Cramer breaks down this market action.

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Ligand Pharmaceuticals Incorporated

INVESTOR ALERT: Kirby McInerney LLP Announces An Investigation Of Shareholder Claims Against Ligand Pharmaceuticals Incorporated

The law firm of Kirby McInerney LLP is investigating potential claims against Ligand Pharmaceuticals Incorporated ("Ligand" or the "Company") (NASDAQ: LGND).

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Ligand Pharmaceuticals Incorporated

Wolf Popper LLP Announces Investigation On Behalf Of Investors In Ligand Pharmaceuticals Incorporated

NEW YORK, Jan. 16, 2019 /PRNewswire/ -- Wolf Popper LLP is investigating potential securities fraud claims on behalf of investors in Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) during the period May 9, 2017 through January 14, 2019, who have...

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Ligand Pharmaceuticals Tumbles After Short-Seller Andrew Left Slams the Stock

Left's firm Citron Research gives the $100+ stock a $35 price target.

Former California Deputy Attorney General And Special Prosecutor With Johnson Fistel Launches Investigation Into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged To Contact Firm

Former California Deputy Attorney General And Special Prosecutor With Johnson Fistel Launches Investigation Into Ligand Pharmaceuticals; Investors Suffering Losses Encouraged To Contact Firm

SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Shareholder Rights Law Firm Johnson Fistel, LLP with the assistance of former California Deputy Attorney General and Special Prosecutor, Tiffany Johnson, Esq.

Ligand To Report Fourth Quarter And Full Year 2018 Results On February 7th

Ligand To Report Fourth Quarter And Full Year 2018 Results On February 7th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report fourth quarter and full year 2018 financial results on February 7, 2019.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EBR.B Downgrades: AGTC, AL, CAMP, GOLD, LGND, SNV Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Notable Friday Option Activity: LGND, CPE, AAOI

Notable Friday Option Activity: LGND, CPE, AAOI

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ligand Pharmaceuticals Inc , where a total volume of 4,974 contracts has been traded thus far today, a contract volume which is representative of approximately 497,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 96.1% of LGND's average daily trading volume over the past month, of 517,610 shares.

Ligand Introduces 2019 Financial Outlook And Raises 2018 Financial Guidance

Ligand Introduces 2019 Financial Outlook And Raises 2018 Financial Guidance

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) introduces its financial outlook for 2019.

Ligand Acquires Milestone And Royalty Rights To PTX-022 From Palvella Therapeutics

Ligand Acquires Milestone And Royalty Rights To PTX-022 From Palvella Therapeutics

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the acquisition of economic rights to PTX-022 from Palvella Therapeutics.

Vernalis Research, A Ligand Company, Achieves Success Milestone In Collaboration With Asahi Kasei Pharma

Vernalis Research, A Ligand Company, Achieves Success Milestone In Collaboration With Asahi Kasei Pharma

Vernalis Research, a Ligand Company, announced the achievement of a £1 million success milestone in its drug discovery collaboration with Asahi Kasei Pharma (AKP).

Ligand Announces OmniAb® Partnership With IMetabolic Biopharma Corporation

Ligand Announces OmniAb® Partnership With IMetabolic Biopharma Corporation

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces it has entered into a worldwide OmniAb partnership with iMetabolic Biopharma Corporation (iMBP), an early stage biopharma company located in Tempe, AZ.

Vernalis Research, A Ligand Company, Achieves Success Milestones In Collaboration With Daiichi Sankyo

Vernalis Research, A Ligand Company, Achieves Success Milestones In Collaboration With Daiichi Sankyo

Vernalis Research, a Ligand Company, announced today that it has earned multiple success milestones under its drug discovery collaboration with Daiichi Sankyo Company, Limited (Daiichi Sankyo) that began in December of 2017.

Ligand Reports Third Quarter 2018 Financial Results

Ligand Reports Third Quarter 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and nine months ended September 30, 2018, and provided an operating forecast and program updates.

Ligand To Participate In Stephens NY Investment Conference

Ligand To Participate In Stephens NY Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in Stephens NY Investment Conference in New York City.

Keysight Technologies Set To Join S&P 500; Ligand Pharmaceuticals To Join S&P MidCap 400; Marcus & Millichap And Arcosa To Join S&P SmallCap 600

Keysight Technologies Set To Join S&P 500; Ligand Pharmaceuticals To Join S&P MidCap 400; Marcus & Millichap And Arcosa To Join S&P SmallCap 600

NEW YORK, Oct. 30, 2018 /PRNewswire/ -- S&P Dow Jones Indices will make the following changes to the S&P 500, S&P MidCap 400 and S&P SmallCap 600: S&P MidCap 400 constituent Keysight Technologies Inc.

Notable Thursday Option Activity: LGND, ARRY, SN

Notable Thursday Option Activity: LGND, ARRY, SN

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Ligand Pharmaceuticals Inc , where a total volume of 3,454 contracts has been traded thus far today, a contract volume which is representative of approximately 345,400 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 56.1% of LGND's average daily trading volume over the past month, of 616,225 shares.

Ligand To Report Third Quarter 2018 Results On November 8th

Ligand To Report Third Quarter 2018 Results On November 8th

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announced today plans to report third quarter 2018 financial results on November 8, 2018.

Ligand Announces The Close Of Its Acquisition Of Vernalis

Ligand Announces The Close Of Its Acquisition Of Vernalis

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that its acquisition of Vernalis plc has successfully closed and Vernalis will now operate as a subsidiary of Ligand.

Fr. Emmanuel Lemelson Responds To SEC Charges

Fr. Emmanuel Lemelson Responds To SEC Charges

MARLBOROUGH, Mass., Sept.

Ligand To Participate In H.C. Wainwright 20th Annual Global Investment Conference

Ligand To Participate In H.C. Wainwright 20th Annual Global Investment Conference

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that the company is scheduled to participate in H.

Ligand Makes Offer To Acquire Vernalis, A Leader In Structure-Based Drug Discovery, For Approximately $43 Million In Cash

Ligand Makes Offer To Acquire Vernalis, A Leader In Structure-Based Drug Discovery, For Approximately $43 Million In Cash

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Vernalis plc (LSE: VER) announce that Ligand has declared its firm intention to acquire the entire issued and to be issued shares of Vernalis through a UK scheme of arrangement conditional on approval...

Ligand Reports Second Quarter 2018 Financial Results

Ligand Reports Second Quarter 2018 Financial Results

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today reported financial results for the three and six months ended June 30, 2018, and provided an operating forecast and program updates.

Ligand Pharmaceuticals Larger Than S&P 500 Component Discovery

Ligand Pharmaceuticals Larger Than S&P 500 Component Discovery

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Ligand Pharmaceuticals Inc was identified as having a larger market cap than the smaller end of the S&P 500, for example Discovery Inc , according to The Online Investor. Market capitalization is an important data point for investors to keep an eye on, for various reasons.

Ligand To Report Second Quarter 2018 Results On August 6th

Ligand To Report Second Quarter 2018 Results On August 6th

Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) announced today plans to report second quarter 2018 financial results on August 6, 2018.

TheStreet Quant Rating: C (Hold)